Cetuximab, a recombinant monoclonal antibody against the epidermal growth factor receptor (EGFR), is the only targeted agent for HNSCC to date that was approved by the Federal Food and Drug Administration (FDA). Here, EGFR is linked to head and neck squamous cell carcinoma.